Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

19.13
+0.58003.13%
Post-market: 19.400.2700+1.41%19:08 EDT
Volume:843.32K
Turnover:16.33M
Market Cap:2.10B
PE:-7.47
High:19.98
Open:18.40
Low:17.77
Close:18.55
Loading ...

NewAmsterdam Pharma Company (NAMS) Gets a Buy from Scotiabank

TIPRANKS
·
11 Dec 2024

New Amsterdam Invest Nv : Scotiabank Raises Target Price to $47 From $35

THOMSON REUTERS
·
11 Dec 2024

NewAmsterdam Pharma Starts $300 Million Offering of Shares, Prefunded Warrants

MT Newswires Live
·
11 Dec 2024

NewAmsterdam Pharma announces $300M offering of ordinary shares, warrants

TIPRANKS
·
11 Dec 2024

NewAmsterdam Pharma price target raised to $48 from $45 at Leerink

TIPRANKS
·
11 Dec 2024

Verve Therapeutics has positive read from NewAmsterdam data, says Stifel

TIPRANKS
·
11 Dec 2024

NewAmsterdam Pharma Says Phase 3 Trial of Obicetrapib Reaches Primary Endpoint; Shares Jump Pre-Bell

MT Newswires Live
·
10 Dec 2024

NewAmsterdam reports data from Phase 3 BROADWAY trial, met primary endpoint

TIPRANKS
·
10 Dec 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Dec 2024

NewAmsterdam Pharma Price Target Maintained With a $36.00/Share by Needham

Dow Jones
·
05 Dec 2024

RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
22 Nov 2024

NewAmsterdam Pharma Reports Promising Phase 3 Trial Results

TipRanks
·
21 Nov 2024

NewAmsterdam Pharma Price Target Maintained With a $36.00/Share by Needham

Dow Jones
·
21 Nov 2024

NewAmsterdam Pharma Company Nv : Leerink Partners Raises Target Price to $45 From $42

THOMSON REUTERS
·
21 Nov 2024

NewAmsterdam Pharma's Anti-Bad Cholesterol Treatment Combination Meets Targets in Phase 3 Trial

MT Newswires Live
·
20 Nov 2024

NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints

Dow Jones
·
20 Nov 2024

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

GlobeNewswire
·
20 Nov 2024

TD Cowen Remains a Buy on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
19 Nov 2024

NewAmsterdam Pharma Company (NAMS) Receives a Buy from Piper Sandler

TIPRANKS
·
19 Nov 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

GlobeNewswire
·
19 Nov 2024